Nutra Pharma Corp.

What they do

Nutra Pharma markets homeopathic OTC pain products built around Asian cobra venom, led by Nyloxin and Nyloxin Extra Strength and extended to Pet Pain-Away, Equine Pain-Away and Luxury Feet. It also has two unapproved drug candidates, RPI-78M for neurological and autoimmune conditions and RPI-MN for viral diseases. It brought manufacturing in-house in March 2022 and since October 2021 has made private-label and contract-manufactured products for third parties, including dietary supplement company Avini Health. Subsidiaries are ReceptoPharm, Inc. and the inactive Designer Diagnostics Inc.

Revenue drivers

• Nyloxin / Nyloxin Extra Strength — The core OTC pain-relief line, sold as topical gel and oral spray through nyloxin.com, the Nyloxin Amazon storefront, Walmart Marketplace, physician offices, clinics and small-chain pharmacies.
• Pet Pain-Away — Over-the-counter pain reliever for cats and dogs launched in December 2014; the 10-Q cites placement on Chewy and expanded Amazon presence as recent distribution gains.
• Equine Pain-Away and Luxury Feet — Equine Pain-Away is a topical horse pain reliever launched October 2019; Luxury Feet, launched March 2021, targets foot pain from high heels. No revenue is broken out for either.
• Contract and private-label manufacturing — Started October 2021; first agreement announced March 2022 to formulate and contract manufacture for dietary supplement company Avini Health, described as a related party.

Recent performance

Annual revenue has grown slowly but steadily, from $97,735 in 2021 to $257,612 in 2025. Net losses were $1.3M in 2024 and $2.0M in 2025, with operating cash flow of negative $423,959 in 2024 and negative $1.2M in 2025. Quarterly revenue has fallen sharply, from $70,242 in the quarter ended 2025-09-30 to $28,864 in 2025-12-31, $27,246 in 2026-03-31 and $34,463 in 2026-06-30. At 2026-06-30 total assets were $622,863 against $21.8M of liabilities, leaving shareholder equity of negative $21.2M. Diluted EPS rounds to $0.00 in 2023 through 2025.

Strategy

Management's stated focus is marketing the homeopathic pain products, with Nyloxin and Nyloxin Extra Strength positioned as non-opioid, non-NSAID alternatives. Since October 2025 the company has used marketing and social media consultants to expand Nyloxin and Pet Pain-Away sales, which it says increased its Amazon footprint and placed Pet Pain-Away on Chewy. It also says it brought all manufacturing in-house in March 2022 to cut product costs, improve margins and speed new launches. Cobroxin, discontinued in 2013, is expected to be reintroduced later in 2026. Longer term the company seeks licensing partnerships for RPI-78M and RPI-MN.

Risks

• Going-concern / negative equity — At 2026-06-30 liabilities of $21.8M exceed total assets of $622,863, producing shareholder equity of negative $21.2M.
• Cash burn and thin liquidity — Operating cash flow was negative $1.2M in 2025 and cash and equivalents were only $12,181 at 2025-12-31, so operations depend on continued outside financing.
• Falling quarterly revenue — Revenue fell from $70,242 in the quarter ended 2025-09-30 to $34,463 in the quarter ended 2026-06-30, despite the added marketing spending.
• Unapproved drug pipeline — RPI-78M and RPI-MN remain subject to FDA approval; the only FDA milestone cited is 2015 Orphan Designation for Pediatric Multiple Sclerosis, not an approval.

Outlook

Management says it will keep marketing Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet domestically and internationally, with recent emphasis on Amazon and Chewy distribution. It expects Cobroxin to be reintroduced later in 2026 and says it is working with outside consultants to register Nyloxin Military Strength, described as roughly twice as strong as Nyloxin Extra Strength. During the second quarter of 2026 the company brought its financial reporting current. No specific revenue or earnings guidance is disclosed.